Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Biphenyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dicyclohexylcarbodiimide SCHEMBL3898262 | 0.82 | EPHX1 (0.39) | DPP4DPP7ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL158703 | 0.70 | NAPRT (0.50) | ALDH1A1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL9068482 | 0.70 | NAPRT (0.50) | ALDH1A1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL16824180 | 0.70 | NAPRT (0.50) | ALDH1A1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL6076010 | 0.68 | NAPRT (0.47) | ALDH1A1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL27559395 | 0.68 | NAPRT (0.47) | ALDH1A1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL27831673 | 0.68 | ALDH1A1 (0.33) | ALDH1A1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL28325627 | 0.67 | TSHR (0.38) | L3MBTL1 | |
| Pyridine SCHEMBL9696216 | 0.66 | NAPRT (0.45) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4182370 | 0.66 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501846-B1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | ABBOTT LAB (US) | 2009-03-18 | — | — | EP | disclosed |
| US-6992069-B2 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2006-01-31 | — | — | US | disclosed |
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | RPN1, CASP1, MRPL21 | DPP4 178/4885DPP7 251/4885ALDH1A1 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.